Peter Bang1, Joachim Woelfle2, Valerie Perrot3, Caroline Sert3, Michel Polak4. 1. Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden. 2. Children's Hospital, University of Erlangen, Erlangen, Germany. 3. Ipsen Pharma, Boulogne-Billancourt, France. 4. Department of Paediatric Endocrinology, Gynaecology, and Diabetology, AP-HP, Necker-Enfants Malades University Hospital, IMAGINE Institute, University of Paris, Paris, France.
Abstract
OBJECTIVE: The European Increlex® Growth Forum Database Registry monitors the effectiveness and safety of recombinant human insulin-like growth factor-1 (rhIGF1; mecasermin, Increlex®) therapy in patients with severe primary IGF1 deficiency (SPIGFD). We present data from patients with and without a reported genetic diagnosis of Laron syndrome (LS). DESIGN: Ongoing, open-label, observational registry (NCT00903110). METHODS: Children and adolescents receiving rhIGF1 therapy from 10 European countries were enrolled in 2008-2017 (n = 242). The treatment-naïve/prepubertal (NPP) cohort (n = 138) was divided into subgroups based on reported genetic diagnosis of LS (n = 21) or non-LS (n = 117). Multivariate analysis of the NPP-non-LS subgroup was conducted to identify factors predictive of growth response (first-year-height standard deviation score (SDS) gain ≥ 0.3). Assessments included change in height and weight over 5 years and adverse events (AEs). RESULTS: Height SDS gain from baseline was greater in the NPP-LS than the NPP-non-LS subgroup after 1 years' treatment (P < 0.05). In the NPP-non-LS subgroup, 56% were responders; young age at baseline was a positive independent predictive factor (P < 0.001). NPP-non-LS-responders and the NPP-LS subgroup had a similar mean age (6.07 years vs 7.00 years) at baseline and height SDS gain in year 1 (0.64 vs 0.70), although NPP-non-LS-responders were taller (P < 0.001) at baseline. BMI SDS changes did not differ across subgroups. Treatment-emergent AEs were experienced by 65.3% of patients; hypoglycaemia was most common. CONCLUSIONS: In most NPP children with SPIGFD, with or without LS, rhIGF1 therapy promotes linear growth. The safety profile was consistent with previous studies.
OBJECTIVE: The European Increlex® Growth Forum Database Registry monitors the effectiveness and safety of recombinant human insulin-like growth factor-1 (rhIGF1; mecasermin, Increlex®) therapy in patients with severe primary IGF1 deficiency (SPIGFD). We present data from patients with and without a reported genetic diagnosis of Laron syndrome (LS). DESIGN: Ongoing, open-label, observational registry (NCT00903110). METHODS: Children and adolescents receiving rhIGF1 therapy from 10 European countries were enrolled in 2008-2017 (n = 242). The treatment-naïve/prepubertal (NPP) cohort (n = 138) was divided into subgroups based on reported genetic diagnosis of LS (n = 21) or non-LS (n = 117). Multivariate analysis of the NPP-non-LS subgroup was conducted to identify factors predictive of growth response (first-year-height standard deviation score (SDS) gain ≥ 0.3). Assessments included change in height and weight over 5 years and adverse events (AEs). RESULTS: Height SDS gain from baseline was greater in the NPP-LS than the NPP-non-LS subgroup after 1 years' treatment (P < 0.05). In the NPP-non-LS subgroup, 56% were responders; young age at baseline was a positive independent predictive factor (P < 0.001). NPP-non-LS-responders and the NPP-LS subgroup had a similar mean age (6.07 years vs 7.00 years) at baseline and height SDS gain in year 1 (0.64 vs 0.70), although NPP-non-LS-responders were taller (P < 0.001) at baseline. BMI SDS changes did not differ across subgroups. Treatment-emergent AEs were experienced by 65.3% of patients; hypoglycaemia was most common. CONCLUSIONS: In most NPP children with SPIGFD, with or without LS, rhIGF1 therapy promotes linear growth. The safety profile was consistent with previous studies.
Authors: Steven D Chernausek; Philippe F Backeljauw; James Frane; Joyce Kuntze; Louis E Underwood Journal: J Clin Endocrinol Metab Date: 2006-12-27 Impact factor: 5.958
Authors: Philippe F Backeljauw; Joyce Kuntze; James Frane; Ali S Calikoglu; Steven D Chernausek Journal: Horm Res Paediatr Date: 2013-07-20 Impact factor: 2.852
Authors: Elżbieta Petriczko; Tomasz Jackowski; Anita Horodnicka-Józwa; Beata Wikiera; Anna Noczyńska; Maria Korpal-Szczyrska; Dorota Birkholz-Walerzak; Ewa Małecka-Tendera; Barbara Kalina-Fraska; Maria Kalina; Ewa Barg; Iwona Beń-Skowronek; Leszek Szewczyk; Maciej Hilczer; Joanna Smyczyńska; Renata Stawerska; Andrzej Lewiński; Katarzyna Ziora; Artur Bossowski; Edyta Pietrewicz; Beata Pyrżak; Andrzej Kędzia; Mieczysław Szalecki; Agnieszka Kilian; Mieczysław Walczak Journal: Endokrynol Pol Date: 2018-10-23 Impact factor: 1.582
Authors: Peter Bang; S Faisal Ahmed; Jesús Argente; Philippe Backeljauw; Markus Bettendorf; Gianni Bona; Régis Coutant; Ron G Rosenfeld; Marie-José Walenkamp; Martin O Savage Journal: Clin Endocrinol (Oxf) Date: 2012-08 Impact factor: 3.478
Authors: Peter Bang; Michel Polak; Valérie Perrot; Caroline Sert; Haris Shaikh; Joachim Woelfle Journal: Front Endocrinol (Lausanne) Date: 2022-02-18 Impact factor: 5.555